Search our Database of Scientific Publications and Authors

I’m looking for a
    Prevalence of Hepatitis A Virus Antibody in Portuguese Travelers: A New Paradigm.
    Acta Med Port 2017 Aug 31;30(7-8):534-540. Epub 2017 Aug 31.
    Serviço de Doenças Infeciosas. Centro Hospitalar e Universitário de Coimbra. Coimbra. Portugal.
    Introduction: In Portugal, the prevalence of hepatitis A virus infection has decreased in the past decades, especially in young adults. The aim of this study was to detect the prevalence of antibody to hepatitis A virus in a population observed in our Travel Clinic.

    Material And Methods: Antibodies against hepatitis A, hepatitis B, hepatitis C and human immunodeficiency virus were tested using standard enzyme immunoassay in patients older than 18. The exclusion criteria were: prior vaccination for hepatitis A virus, previous diagnosis of infection with hepatitis B virus, hepatitis C virus and/or human immunodeficiency virus, foreign travelers and long-term expatriates. We applied an epidemiological survey and data was statistically analyzed with SPSS® 18.0.

    Results: In the 665 travelers studied, natural immunity to hepatitis A virus was present in 57.6% (n = 383). They were stratified into 8 age groups and for each one hepatitis A immunity was clarified: 5.0% (n = 1) in 18 - 25 years, 32.3% (n = 21) in 26 - 30 years, 40.9% (n = 47) in 31 - 35 years, 45.8% (n = 54) in 36 - 40 years, 68.7% (n = 79) in 41 - 45 years, 70.1% (n = 68) in 46 - 50 years, 80.8% (n = 63) in 51 - 55 years and 87.7% (n = 50) over 56 years old. In those who accepted further screening, positivity for hepatitis B core antibody was found in 0.6% (n = 3) travelers, hepatitis C virus infection in 1.1% (n = 6) and human immunodeficiency virus infection in 0.5% (n = 3) whose previous status was unknown. The most frequent travel destination was sub-Saharan Africa (72.6%; n = 483).

    Discussion: We found 49.1% (n = 260) travelers under 50 years old susceptible to hepatitis A virus infection and for those between 40 and 50 years, 30.7% (n = 65) still need vaccine protection.

    Conclusion: Across age groups there is a trend towards lower prevalence of hepatitis A virus antibody, in particular among youngsters, when compared with older Portuguese studies.

    Similar Publications

    Hepatitis B screening in travelers: a retrospective analysis.
    Travel Med Infect Dis 2014 Nov-Dec;12(6 Pt B):707-12. Epub 2014 Jul 17.
    Institut Pasteur, Centre Médical, 209 rue de Vaugirard, 75015 Paris, France. Electronic address:
    Background: Non-immune travelers are at risk of acquiring hepatitis B (HB) in high prevalence countries.

    Method: At the Institut Pasteur Vaccination Center in a retrospective study we retrieved hepatitis B serological data from the vaccination database between 2008 and 2012. Serology (HBsAg, HBsAb and HBcAb) is proposed to travelers who have no information about their previous HB vaccination status if they travel to countries of high or intermediate prevalence of HB, for long or frequent trips. Read More
    Prevalence of Hepatitis A Antibody in Travelers from Hawaii.
    J Travel Med 1996 Mar;3(1):27-31
    Tropical and Travel Medicine, Kaiser Permanente, and Associate Professor, University of Hawaii, Honolulu, Hawaii, U.S.A.
    Background: Hepatitis A is the most frequent vaccine-preventable infection in travelers to developing countries. Hepatitis A vaccine and immune serum globulin (IG) offer safe, effective protection against hepatitis A. Some travelers are already immune, however, and it is useful to try to identify subgroups with an anticipated high prevalence of antibody to hepatitis A (anti-HAV). Read More
    Vaccination strategies against hepatitis A in travelers older than 40 years: an economic evaluation.
    J Travel Med 2009 Sep-Oct;16(5):344-8
    Preventive Medicine and Epidemiology Department, Hospital Clinic/IDIBAPS, Barcelona, Spain.
    Background: In recent years, the number of travelers aged >40 years who acquire hepatitis A while traveling has increased. Therefore, there is a need to review hepatitis A vaccination protocols in travelers. The aims of the study were to assess immunity levels to hepatitis A virus (HAV) in international travelers >40 years and to determine the least costly immunization strategy. Read More
    Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States.
    Vaccine 2013 May 21;31(19):2348-57. Epub 2013 Mar 21.
    Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, NE, Atlanta, GA 30333, United States.
    Background: Since 1996, hepatitis A vaccine (HepA) has been recommended for adults at increased risk for infection including travelers to high or intermediate hepatitis A endemic countries. In 2009, travel outside the United States and Canada was the most common exposure nationally reported for persons with hepatitis A virus (HAV) infection.

    Objective: To assess HepA vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity in the United States. Read More